Tenofovir Disoproxil FumarateDisoproxil Fumarate能阻断HIV-1和HBV的逆转录酶,对HIV-1和HIV-2的IC50分别为0.5-2.2 uM和1.6-4.9 uM。
Tenofovir Disoproxil Fumarate belongs to a class of antiretroviral drugs, it inhibits the activity of HIV reverse transcriptase by competing with the natural substrate deoxyadenosine 5’-triphosphate and, after incorporation into DNA, by DNA chain termination.
动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数 | |
例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。
[1] Ray AS, et al. Antimicrob Agents Chemother, 2006, 50(10), 3297-3304.
[2] DeChristoforo R, Penzak SR. Tenofovir: a nucleotide analogue reverse-transcriptase inhibitor for treatment of HIV infection. Am J Health Syst Pharm. 2004 Jan 1;61(1):86-98; quiz 99-100.
[3] Menne S, Cote PJ, Korba BE, Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob Agents Chemother. 2005 Jul;49(7):2720-8.
分子式 C23H34N5O14P |
分子量 635.51 |
CAS号 202138-50-9 |
储存方式 ﹣20 ℃冷藏长期储存。冰袋运输 |
溶剂(常温) |
DMSO 128 mg/mL |
Water <1 mg/mL |
Ethanol 44 mg/mL |
体内溶解度
NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
NCT02533544 | Chronic Hepatitis B | Drug: tenofovir disoproxil fumarate | Myeong Jun Song|Gilead Sciences|Wonkwang University|Soonchunhyang University Hospital|Chungnam National University Hospital|Konyang University Hospital|The Catholic University of Korea | 2015-10-01 | 2016-06-01 | |
NCT02195518 | Hepatitis B, Chronic | Drug: Tenofovir disoproxil fumarate | GlaxoSmithKline | Phase 4 | 2015-03-01 | 2016-08-03 |
NCT00648817 | HIV Infections | Drug: Tenofovir Disoproxil Fumarate|Drug: Tenofovir DF placebo | Gilead Sciences | Phase 4 | 2006-07-01 | 2008-03-31 |
NCT02589457 | Chronic Hepatitis B | Drug: CKD-390|Drug: Viread tablet | Chong Kun Dang Pharmaceutical | Phase 1 | 2015-10-01 | 2016-01-11 |
NCT02463019 | Chronic Hepatitis B|Antiviral Treatment | Drug: Tenofovir Disoproxil Fumarate | E-DA Hospital|Taipei Institute of Pathology | Phase 4 | 2015-01-01 | 2015-06-02 |
NCT01671787 | Chronic Hepatitis B | Drug: GS-7340|Drug: Tenofovir disoproxil fumarate | Gilead Sciences | Phase 1 | 2012-03-01 | 2014-05-08 |
NCT00734162 | Hepatitis B Virus (HBV) | Drug: Tenofovir disoproxil fumarate (TDF)|Drug: Placebo | Gilead Sciences | Phase 3 | 2008-12-01 | 2016-07-20 |
NCT03070405 | Healthy Volunteers | Drug: Tenofovir disoproxil fumarate 300mg|Drug: Para-aminosalicylic acid Ca granule 5.28 g | Inje University | Phase 1 | 2016-10-01 | 2017-03-02 |
NCT01334567 | Hepatitis B | Drug: Tenofovir DF | Gilead Sciences | Phase 2 | 2010-08-01 | 2014-02-28 |
NCT02280109 | Healthy|HIV | Drug: Tenofovir Gel|Drug: Tenofovir Film | CONRAD|National Institute of Allergy and Infectious Diseases (NIAID) | Early Phase 1 | 2014-11-01 | 2016-01-27 |
NCT02557594 | Healthy | Drug: Viread 300mg|Drug: DA-2802 319mg | Dong-A ST Co., Ltd. | Phase 1 | 2015-10-01 | 2015-09-22 |
NCT02995005 | Hepatitis B | Drug: Tenofovir Disoproxil Fumarate | Johns Hopkins Bloomberg School of Public Health|Thrasher Research Fund|Shoklo Malaria Research Unit|Chiang Mai University | Phase 1|Phase 2 | 2017-08-01 | 2017-02-28 |
NCT02530060 | Healthy | Drug: Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine FDC | Janssen Pharmaceutical K.K. | Phase 4 | 2015-08-01 | 2016-12-30 |
NCT02510963 | Hepatitis B, Chronic | Drug: Tenofovir Disoproxil Fumarate|Drug: Tenofovir Disoproxil Fumarate|Drug: Tenofovir Disoproxil Fumarate | First Affiliated Hospital Xi'an Jiaotong University | 2015-11-01 | 2016-08-09 | |
NCT02479880 | Hepatitis B | Drug: Tenofovir DF|Radiation: DEXA Scan | Gilead Sciences | Phase 4 | 2015-07-01 | 2017-01-12 |
NCT00736190 | Chronic Hepatitis B | Drug: Tenofovir disoproxil fumarate | Gilead Sciences | Phase 4 | 2008-08-01 | 2011-11-30 |
NCT01711567 | Chronic Hepatitis B | Drug: tenofovir|Drug: entecavir | Korea University|Gilead Sciences | Phase 4 | 2013-04-01 | 2016-11-08 |
NCT01872988 | Chronic Hepatitis B|Hepatocellular Carcinoma | Drug: Tenofovir|Drug: Placebo | Taichung Veterans General Hospital|Gilead Sciences|Taipei Institute of Pathology | Phase 3 | 2012-09-01 | 2014-09-03 |
NCT03032536 | Hepatitis B|Chronic Hepatitis B|Viral Hepatitis B | Drug: AL-3778|Drug: Entecavir|Drug: Tenofovir disoproxil fumarate | Alios Biopharma Inc. | Phase 1 | 2017-01-31 | 2017-02-09 |
NCT00507507 | Chronic Hepatitis B | Drug: Tenofovir DF|Drug: FTC|Drug: Placebo | Gilead Sciences | Phase 2 | 2007-09-01 | 2015-07-07 |
NCT00903084 | HIV | Drug: Tenofovir Disoproxil Fumarate | Public Health Foundation Enterprises, Inc.|National Institute of Mental Health (NIMH) | Phase 1 | 2009-06-01 | 2015-04-02 |
NCT01522625 | Chronic Hepatitis B | Drug: tenofovir disoproxil fumarate 300mg per day|Drug: Placebo | E-DA Hospital|Gilead Sciences|Taipei Institute of Pathology | Phase 4 | 2012-01-01 | 2017-03-20 |
NCT01491295 | Chronic Hepatitis B | Drug: Tenofovir disoproxil fumarate|Drug: Lamivudine plus adefovir | Taipei Veterans General Hospital, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital|China Medical University Hospital|Chi Mei Medical Hospital|Chiayi Christian Hospital | Phase 4 | 2012-09-01 | 2016-03-31 |
NCT02722343 | HIV | Drug: Tenofovir intravaginal ring|Drug: Truvada | CONRAD|Eastern Virginia Medical School|University of North Carolina|Agility Clinical, Inc. | Phase 1 | 2016-04-01 | 2016-09-01 |
NCT01074645 | Acute on Chronic Liver Failure|Hepatitis B | Drug: Tenofovir disoproxil fumarate (TDF) | Govind Ballabh Pant Hospital | Phase 4 | 2007-11-01 | 2010-02-23 |
注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。
相关化合物库
使用AMQUAR产品发表文献后请联系我们